Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Albert Einstein Medical Center

Neither a doctor nor a teaching hospital

Research payments

$94,814

29 payments

Through program year 2023, Albert Einstein Medical Center is reported as receiving $94,814 in research payments, across 29 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $750 1
2022 Research $29,556 4
2021 Research $5,544 3
2020 Research $3,900 1
2019 Research $55,063 20

Breakdown

Who paid Research payments · program years 2019–2023
  1. Mercator MedSystems, Inc. $28,956 3 payments
  2. Ipsen Biopharmaceuticals, Inc $26,528 2 payments
  3. AstraZeneca Pharmaceuticals LP $17,472 2 payments
  4. Surmodics, Inc. $11,064 16 payments
  5. Pfizer Inc. $5,350 2 payments
  6. Novartis Pharmaceuticals Corporation $3,900 1 payment
  7. Impulse Dynamics (USA) Inc. $1,350 2 payments
  8. Merck Sharp & Dohme Corporation $194 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. Video and Temporal Spatial Parameters Assessment of Gait After Dysport Treatment. A Pilot Study $26,528 2 payments
  2. A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes $17,472 2 payments
  3. Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization $14,980 1 payment
  4. TANGO: Temsirolimus Dventitial Delivery to Improve ANGiographic Outcomes Below the Knee $13,226 1 payment
  5. Transcend $11,064 16 payments
  6. A Phase 2A Randomized Doubleblind Placebocontrolled 3Arm Parallel Group Study to Evaluate Safety Tolerability and Pharmacodynamics of Pf06835919 Administered Daily for 16 Weeks in Adults With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus on Metformin $5,350 2 payments
  7. Exploring the Safety and Tolerability of Conversion to Dose Titrated Siponimod in Patients With Relapsing Forms of Multiple Sclerosis A 6 Month Open Label Multi Center Phase III B Study Expanded $3,900 1 payment
  8. Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy $1,350 2 payments
  9. Perivenous Dexamethasone Therapy: Examing Reduction of Inflammation after Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT $750 1 payment
  10. A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B MK-5172 MK-3682 MK-8408 Fixed Dose Combination FDC in Subjects with Chronic HCV GT1 or GT3 Infection who have failed a Direct Acting Antiviral Regimen $194 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record